4.3 Article

Breastfeeding and tacrolimus: is it a reasonable approach?

Journal

EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 9, Issue 7, Pages 623-626

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2013.811042

Keywords

breastfeeding; pregnancy; tacrolimus; transplantation

Categories

Funding

  1. Novartis Pharmaceuticals Corporation
  2. Astellas Pharma US Inc.
  3. Genentech Inc.
  4. Pfizer Inc.
  5. Teva Pharmaceuticals USA
  6. Sandoz Inc
  7. Bristol-Myers Squibb Company

Ask authors/readers for more resources

Evaluation of: Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. CJASN 8(4), 563-567 (2013). Successful pregnancy after transplantation has become more common and more recipients are choosing to breastfeed their infants, despite the controversy surrounding the safety of breastfeeding while the mother is taking immunosuppressive medications, such as tacrolimus. Data collected to date by the National Transplantation Pregnancy Registry have not revealed specific problems related to breastfeeding; however, individual circumstances must be considered when counseling transplant recipients regarding breastfeeding. Bramham et al. reported on a series of transplant recipients who were maintained on tacrolimus during pregnancy and lactation and concluded that women should not be discouraged from breastfeeding while on tacrolimus. Recently, other authors have also supported the option of breastfeeding while recipients are maintained on tacrolimus. Herein, we review the Bramham article and discuss the key issues to be considered regarding the compatibility of breastfeeding and immunosuppression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available